Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)
Authors
K. Eyerich
Christopher G. Bunick (ORCID: https://orcid.org/0000-0002-4011-8308)
Charles W Lynde (ORCID: https://orcid.org/0000-0001-9163-5463)
Brian Calimlim (ORCID: https://orcid.org/0000-0002-6463-6433)
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)
K. Eyerich, Christopher G. Bunick, Charles W Lynde, Brian Calimlim et al.
Journal
American Journal of Clinical Dermatology
Topics
Dermatology and Skin Diseases
article
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)
K. Eyerich, Christopher G. Bunick, Charles W Lynde, Brian Calimlim, Riichiro Abe, Y. Armendáriz, Angela Moore, Nadia Ibrahim, Gweneth Levy, Xinghua Gao, Nina Magnolo, Xiaoqiang Wu
article en
Abstract
No abstract available for this paper.
Publication Tag
American Journal of Clinical DermatologyVol. 27(2)
Institutions
University of Freiburg (DE), University Medical Center Freiburg (DE), Baylor University Medical Center (US), AbbVie (United States) (US), Yale University (US), Lynde Centre for Dermatology (CA), University Hospital Münster (DE), Arlington Center for Dermatology (US), China Medical University (CN)